Scholarlink

<p>Health technology assessments (HTAs) for targeted therapies like osimertinib require models capturing individual pharmacokinetic/pharmacodynamic (PK/PD) variability in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Traditional models often fail to reflect these dynamics adequately. This study compared a pharmacometric-based model (PMX) with four traditional frameworks to evaluate osimertinib’s cost-utility from a healthcare payer perspective. A virtual cohort of 1,000 patients with advanced EGFR-mutant NSCLC received osimertinib (80&#xa0;mg daily) or comparator first-line EGFR-tyrosine kinase inhibitors (gefitinib/erlotinib). Models projected survival, adverse events (AEs), quality-adjusted life years (QALYs), and costs over 2&#xa0;years. ICURs used PMX as benchmark. The PMX model yielded highest QALYs (1.48) and lowest ICUR ($82,000/QALY vs. comparator), outperforming traditional models (ICUR deviations − 21% to + 40%). TTE exponential showed most divergence due to constant hazard. Probabilistic analyses confirmed PMX superiority across willingness-to-pay thresholds. Pharmacometric models, enabling individualized dosing and exposure-driven effects, provide more biologically plausible estimates, supporting their integration into HTAs for precision oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models

  • 期刊论文

  • 发表日期：

    2026年3月28日

查看全文
  • Gloria Nnadwa Alhassan

摘要

Health technology assessments (HTAs) for targeted therapies like osimertinib require models capturing individual pharmacokinetic/pharmacodynamic (PK/PD) variability in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Traditional models often fail to reflect these dynamics adequately. This study compared a pharmacometric-based model (PMX) with four traditional frameworks to evaluate osimertinib’s cost-utility from a healthcare payer perspective. A virtual cohort of 1,000 patients with advanced EGFR-mutant NSCLC received osimertinib (80 mg daily) or comparator first-line EGFR-tyrosine kinase inhibitors (gefitinib/erlotinib). Models projected survival, adverse events (AEs), quality-adjusted life years (QALYs), and costs over 2 years. ICURs used PMX as benchmark. The PMX model yielded highest QALYs (1.48) and lowest ICUR ($82,000/QALY vs. comparator), outperforming traditional models (ICUR deviations − 21% to + 40%). TTE exponential showed most divergence due to constant hazard. Probabilistic analyses confirmed PMX superiority across willingness-to-pay thresholds. Pharmacometric models, enabling individualized dosing and exposure-driven effects, provide more biologically plausible estimates, supporting their integration into HTAs for precision oncology.